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Malignant adnexal tumors of the skin: a
single institution experience
Tolutope Oyasiji2* , Wei Tan1, John Kane III1, Joseph Skitzki1, Valerie Francescutti1, Kilian Salerno1
and Nikhil I. Khushalani1
Abstract
Background: Malignant adnexal tumors of the skin (MATS) are rare. We aimed to measure the survival of patients
with MATS and identify predictors of improved survival.
Methods: A retrospective review of MATS treated at our institution from 1990 to 2012.
Results: There were 50 patients within the time period. Median age was 59.5 years (range 22–95); primary site was
the head and neck (52%); most common histologic subtypes were skin appendage carcinoma (20%) and eccrine
adenocarcinoma (20%); and the vast majority were T1 (44%). Most patients (98%) underwent surgical treatment.
Chemotherapy and radiation were administered to 8 and 14% of patients, respectively. Recurrence rate was 12%.
Median OS was 158 months (95% CI, 52–255). OS and recurrence-free survival at 5 years were 62.4 and 47.4% and
at 10 years 56.7 and 41.5%, respectively. Five-year and 10-year disease-specific survival (DSS) was 62.9%. Age
> 60 years was an unfavorable predictor of OS (HR 12.9, P < .0008) and recurrence-free survival (RFS) (HR 12.53,
P < .0003). Nodal metastasis was a negative predictor of RFS (HR 2.37, P < 0.04) and DSS (HR 7.2, P < 0.03)
while treatment with chemotherapy was predictive of poor DSS (HR 14.21, P < 0.03).
Conclusions: Younger patients had better OS and RFS. Absence of nodal metastasis translated to better RFS
and DSS. Lymph node basin staging is worth considering in the workup and treatment.
Keywords: Malignant, Adnexal, Tumors, Skin, Survival, Treatment
Background
Malignant adnexal tumors of the skin (MATS) are a hetero-
geneous group of rare tumors without consensus on man-
agement guidelines. There are different histologic entities
based on varying differentiation from eccrine, apocrine, se-
baceous, sweat duct, or ceruminous glands within the skin
or follicular cells [1]. They vary in behavior and malignant
potential and pose a diagnostic challenge for pathologists
and surgeons [2]. Paucity of scientific information on these
tumors is reflected by the fact that categorization under the
WHO classification of skin carcinomas was performed only
in 2005 [3]. The AJCC staging for non-melanoma and
non-Merkel cell skin tumors is applied to this group of tu-
mors. The age-adjusted incidence rate for MATS is 5.1 per
one million person-years. The incidence rate among men is
statistically significantly higher than women (6.3 vs 4.2,
respectively; male to female incidence rate ratio is 1.51;
P < .001). The incidence rates for these tumors have in-
creased by as much as 150% in the last three decades
making it imperative that we expand our understanding
of these tumors to make informed decisions regarding
prognosis and treatment [4]. With this in mind, we
sought to define our experience in MATS.
Methods
A retrospective review of all MATS treated at the Roswell
Park Cancer Institute between January 1, 1990, and August
31, 2012, was carried out. An institutional review board ap-
proval was obtained for the study. These patients were
identified through the Institute’s tumor registry. Relevant
demographic, clinical, staging, pathologic, and outcome
data were obtained for each patient. Adult patients aged
18 years and above with histologic diagnosis of malignant
adnexal tumors of the skin were included in the study.
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Patients with concurrent diagnosis of squamous cell carcin-
oma, basal cell carcinoma, and melanoma were excluded.
Descriptive characteristics like frequencies were com-
puted for categorical variables like gender, histologic
diagnosis, primary site of disease, and type of surgical
treatment, while numeric variables were summarized
using mean with standard deviation, median, and range.
We determined overall survival, disease-specific survival,
and recurrence-free survival for our series (Figs. 1, 2 and 3).
Overall survival was defined as the time between the date of
diagnosis and the date of death or the date of last follow-up
or August 31, 2012. Disease-specific survival was defined as
the time between the date of diagnosis and the date of death
specifically from MATS, while recurrence-free survival was
the time between initial treatment of disease and local, re-
gional, or systemic recurrence of disease.
Overall, recurrence-free, and disease-specific survival
analyses were done using the Kaplan-Meier method. Uni-
variate and multivariate analyses were done, using Cox
proportional hazards regression models, to determine pre-
dictors of overall survival, recurrence-free survival, and
disease-specific survival. Variables used in the regression
analyses include age, gender, primary site of disease, histo-
logic subtype, type of surgical treatment, chemotherapy,
radiation treatment, histologic grade, and TNM stage.
Results
Patient characteristics
Fifty patients were identified in this analysis. Fifty-six
percent (28) of patients in our series were males, while
52% (26) were less than or 60 years old (Table 1). The
median and mean ages for the series were 59.5 and
62.4 years, respectively.
Tumor characteristics
Over half of the series (56%) involved the head and neck
region (Table 1). The histology subtypes are outlined in
Table 3. Perineural invasion and lymphovascular invasion
were uncommonly observed at 4 and 2%, respectively
(Table 1). Twenty-nine patients (58%) had undocumented
histologic grades, while intermediate and poor grades of
differentiation constituted 16% each. The remaining 10%
were well differentiated (Table 1).
Treatment
Altogether, 49 patients [98%] underwent surgery-wide local
excision (30%), Moh’s micrographic surgery (22%), and sim-
ple excision (46%) (Table 1). One patient with skin append-
age carcinoma involving the eyebrow was treated primarily
with chemotherapy (carboplatin and taxol) followed by ra-
diation (70 Gy). Four patients (8%) received chemotherapy.
Three of whom were treated adjuvantly, while one was pri-
mary systemic chemotherapy. Out of the three which re-
ceived adjuvant chemotherapy, one was treated with
radiotherapy as well. Single-agent regimen was adminis-
tered to two patients using cisplatin and paclitaxel, respect-
ively. The remaining two patients received multiple-agent
regimen. One was treated with carboplatin and paclitaxel,
while the other received adriamycin, cytoxan, and pacli-
taxel. The indications for chemotherapy were nodal metas-
tasis (2 patients), positive margin and perineural invasion (1
patient), and aggressive disease with periorbital involvement
which would have necessitated extensive resection with or-
bital exenteration in an octogenarian. Seven patients had
radiotherapy—two of whom also had chemotherapy (as in-
dicated above). Out of these seven patients, six received ra-
diation as adjuvant treatment while one received radiation
Fig. 1 Overall survival curve
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as part of definitive chemoradiation. The indications for ra-
diation were locally aggressive disease, perineural invasion,
and nodal metastasis.
Recurrence
The recurrence rate was 12%—three local recurrences,
one regional recurrence, and two distant recurrences.
Two of the local recurrences involved the lower ex-
tremity, while one occurred in the head and neck re-
gion. The distant recurrences were from head and
neck primaries which metastasized to the groin and
brain. The only regional occurrence was from a
primary on the face which recurred in another area
of the face. The pattern is such that two thirds of pa-
tients with recurrent disease had primary site in the
head and neck region while the remaining one third
had lower extremity as the primary site. The histo-
logic subtypes for patients with recurrent disease in-
clude adenoid cystic carcinoma (2 patients), skin
appendage carcinoma (2 patients), eccrine adenocar-
cinoma (1 patient), and sebaceous adenocarcinoma (1
patient). Time to recurrence ranged between 12.9 and
56 months, with the median time to recurrence of
20.3 months.
Fig. 2 Disease-specific survival curve
Fig. 3 Recurrence-free survival curve
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Survival
The median overall survival for our series was
158 months (95% CI 52, 255 months). Five-year OS was
62.4% (95% CI 43.4, 76.6), while the 10-year OS was
56.7% (95% CI 36.4–72.7). Univariate analysis showed
that advanced age (greater than 60 years) was a negative
predictor (P = 0.001) of OS (Table 1). Both 5-year and
10-year disease-specific survival was 62.9% (95% CI
39.3–79.4). Nodal disease (P = 0.03) and treatment with
chemotherapy (P = 0.02) were associated with worse
disease-specific survival (DSS) on univariate analysis
(Table 1). The recurrence-free survival rate was 47.4%
(95% CI 28.2–64.4) at 5 years and 41.5% (95% CI 22.21–
59.8) at 10 years. Age greater than 60 years (P = 0.02),
advanced T stage (P = 0.04), and nodal disease (P = 0.03)
were negative predictors of recurrence-free survival
(RFS) on univariate analysis (Table 1).
On multivariate analysis, age greater than 60 years
(P = 0.0008, HR = 12.9) was an independent negative
predictor of overall survival. The presence of nodal
disease (P = 0.03, HR = 7.2) and treatment with chemo-
therapy (P = 0.03, HR = 14.2) turned out as independent
negative predictors of DSS. Similarly, advanced age
(P = 0.0003, HR 12.5) and nodal disease (P = 0.04, HR
2.4) were independently predictive of higher incidence
of recurrence on multivariate analysis (Table 2).
Discussion
Previous studies have reported median ages ranging
from 68 to 70 years [1, 4, 5]. The mean and median ages
reported for our series were closer to those reported in a
48-patient series of microcystic adnexal carcinoma/scler-
osing sweat duct carcinoma [6], which constituted 12%
of histologic subtypes in our series (Table 3). Advanced
age greater than 60 years was independently predictive
of poor overall and recurrence-free survival in our study.
Table 1 Demographics and univariate analysis
Patient characteristics Number (%) OS DSS RFS
Age
≤ 60 years 26 (52) 0.001 0.89 0.02
> 60 years 24 (48)
Sex
Male 28 (56) 0.73 0.25 0.19
Female 22 (44)
Primary site
Head and neck 26 (52)
Trunk 8 (16) 0.96 0.87 0.53
Upper extremities 8 (16)
Lower extremities 8 (16)
T stage



















Present 2 (4) – – –
Absent 48 (96)
Lymphovascular invasion
Present 1 (2) – – –
Absent 49 (98)
Type of surgery
Wide excision 15 (30) 0.47 0.39 0.17
Mohs surgery 11 (22)
Local excision 23 (46)
Chemotherapy
Yes 4 (8) 0.40 0.02 0.13
No 46 (92)
Table 1 Demographics and univariate analysis (Continued)
Patient characteristics Number (%) OS DSS RFS
Radiation treatment
Yes 7 (14) 0.42 0.06 0.47
No 43 (86)
Recurrence




Distant 2 (4) 0.98 – –
Local 3 (6)
Regional 1 (2)
Limited observations in perineural invasion, lymphovascular invasion, and
recurrence precluded their inclusion in the univariate analysis for OS, DSS,
and RFS
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This aligned well with the findings in other series where
poor OS was observed on univariate analysis for patients
with age greater than 70 years. Martinez et al. and Avra-
ham et al. reported OS and DSS advantage with the fe-
male gender [1, 5], but gender was not predictive of OS,
DSS, or RFS in our series. However, gender distribution
showed male predominance (56%) in our study, a finding
concordant with the Blake’s series [4] but in contrast
with other studies [3, 7].
Over half (52%) of the MATS in our series were located
in the head and neck region. This is consistent with most
series [1, 4, 5]. The remaining anatomic sites (upper ex-
tremities, lower extremities, and trunk) had equal distribu-
tion of 16% each. The vast majority had early T stage
disease, with 44% being T1. The proportion of unknown
T stage (Tx) in our series was about half of those in two
large population-based series which reported Tx in the
range of 46–56% [1, 4]. Advanced T stage was a negative
predictor of recurrence-free survival on univariate analysis
(P = 0.04), but this trend failed to persist on multivariate
analysis. Unlike squamous cell carcinoma of the skin and
melanoma [8, 9], there was no association between T stage
and nodal metastasis. No patient in our series had distant
metastasis on presentation, although as many as 40% were
documented as unknown M stage. Two distant recur-
rences were documented for adenoid cystic carcinoma
and skin appendage carcinoma, with primaries in the head
and neck region. Distant metastases were recorded in the
literature for nodular hidradenocarcinoma, eccrine
porocarcinoma, apocrine carcinoma [10], and microcystic
adnexal carcinoma [11]. The histologic grade of the tu-
mors was not predictive of OS, DSS, and RFS on univari-
ate and multivariate analysis in our series. Caution,
however, must be exercised as 58% of patients did not
have documented histologic grade. This is a reflection of
how pathology reporting system for this group of tumors
has evolved over the years, with grade reported for the
more recent cases. This trend was similarly observed in
other series, with undocumented histologic grades in the
range of 76 to 81% of patients [1, 5]. A study reported sur-
vival advantage for well-differentiated tumors on univari-
ate analysis, but this variable was not predictive on
multivariate analysis [5]. Another study also demonstrated
survival advantage with better histologic grades, albeit
after excluding patients with distant metastasis [1]. We
did not identify any histologic subtype with survival ad-
vantage in our analysis. The existing literature, however,
showed a mixed picture, with some reporting an advan-
tage for microcystic adnexal carcinoma [5], while other
studies favored sebaceous adenocarcinoma [4, 12] or apo-
crine adenocarcinoma [1].
Surgical nodal staging was done for 12% of the patients
in our series. Histopathologic nodal evaluation varied from
11 to 29% in the literature. There were no standardized cri-
teria for selecting patients who required nodal sampling.
Sixty-six percent (4 out of 6) of patients who had nodal
basin evaluation in our series underwent the procedure be-
cause of clinically positive lymph nodes. One patient had
sentinel lymph node biopsy done based on surgeon’s clin-
ical decision, while the sixth patient had the procedure
done due to unfavorable histologic criteria (poor differenti-
ation and lymphovascular invasion). In a similarly sized
series of 48 patients, nodal sampling was done for nine pa-
tients (18.8%) who developed local recurrence [13]. Four
out of these nine patients demonstrated nodal metastasis.
This group of researchers advocated for nodal sampling in
patients with recurrent disease who presumably were prese-
lected by their aggressive biology. On the other hand, Ogata
et al., in a series of nine patients with apocrine carcinoma
who had wide local excision and routine regional lymph
node dissection, showed nodal disease in all but one patient
[14]. This group called for routine nodal staging, at least for
apocrine carcinoma. Experience from breast cancer and
Table 2 Multivariate analysis for OS, DSS, and RFS
HR (hazard ratio), 95% CI, and P value
OS DSS RFS
Patient characteristics
Age ≤ 60 years 12.90 (2.87–57.95), 0.0008 – 12.53 (3.21–48.95), 0.003
> 60 years
Nodal metastasis – 7.22 (0.722–72.186), 0.03 2.37 (0.22–25.05), 0.04
Chemotherapy – 14.21 (1.27, − 158.91), 0.03 –
Table 3 Histologic subtypes
Histology Number (%)
Skin appendage carcinoma 10 (20)
Eccrine adenocarcinoma 10 (20)
Sebaceous adenocarcinoma 9 (18)
Malignant eccrine poroma 6 (12)
Sclerosing sweat duct adenocarcinoma 6 (12)
Adenoid cystic carcinoma 5 (10)
Malignant eccrine spiradenoma 1 (2)
Malignant nodular hidradenoma 1 (2)
Porocarcinoma 1 (2)
Apocrine adenocarcinoma 1 (2)
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melanoma has shown that nodal metastasis can be present
in the absence of clinically positive lymph nodes. Since
nodal basin is grossly under evaluated, we do not have ac-
curate information yet on incidence of nodal metastasis
and its effect on recurrence and survival. It is worthwhile to
evaluate MATS population with nodal metastasis with a
view to determine predictors of nodal metastasis and then
prospectively validate identified predictors. Prospective val-
idation requires a larger cohort of patients which is always
a challenge when addressing key issues on these rare tu-
mors. Same could be said to apply to histologic criteria like
grade, perineural invasion, and angiolymphatic invasion.
These have been shown to be important in prognostication
for melanoma and many gastrointestinal cancers. If vali-
dated, they should be incorporated into the staging system
which means pathologists would report these features. Due
to limited observations in these categories, we did not in-
clude them in our survival analysis. Only 4% of patients in
our series were positive for perineural invasion and 2% for
lymphovascular invasion. We observed most studies on
MATS did not address these two important criteria.
The role of adjuvant radiation and chemotherapy is not
well defined for MATS. To address this, we need a combin-
ation of large study population and details on regimen of
treatment. Previous studies with much lower number of pa-
tients than our series had reported on adjuvant chemoradia-
tion. The large population-based series from SEER database
were limited, as there was no information on chemotherapy
while radiation treatment was documented as a categorical
variable without detailed information on selection criteria
and dose. Unfortunately, for rare and heterogeneous tumors
like MATS, this will always be challenging. Current pro-
posals on the role of adjuvant radiation support the use of
postoperative radiotherapy for cases in which sufficient re-
section margins cannot be achieved because of the anatomic
site of the lesion or with positive resection margins [14, 15].
There are no defined guidelines/protocols for adjuvant
chemotherapy in the management of MATS, but there are
reported cases of recurrent or metastatic diseases treated
with chemotherapeutic and targeted agents [16]. Various
chemotherapeutic agents like doxorubicin, mitomycin, vin-
cristine, 5-fluorouracil, cyclophosphamide, anthracycline,
bleomycin, paclitaxel, cisplatin, and carboplatin were used in
different combinations for metastatic disease [17, 18]. Re-
sults varied from no response to stable disease and partial re-
sponse. This trend was noticed in all four patients (8%) who
received chemotherapy in our series. The histologic subtypes
represented in this subgroup were adenoid cystic carcinoma,
eccrine adenocarcinoma, apocrine adenocarcinoma, and skin
appendage carcinoma. Chemotherapeutic agents utilized
were cisplatin, carboplatin, adriamycin, cytoxan, and pacli-
taxel. Drawing inference from the apocrine-eccrine origin of
many of these tumors, some proponents have made a case
for treatment with chemotherapy regimen used for breast
cancer. For our series, 4% received adjuvant chemotherapy
alone, 10% were treated with adjuvant radiation alone, and
4% received adjuvant chemoradiation. The survival analysis
showed poor RFS for patients treated with chemotherapy.
These patients may have been preselected by the aggressive
biology of their tumors. The role of chemotherapy in these
patients needs further study. Treatment with radiation, while
not associated with poor survival outcome, did not translate
to survival advantage either.
Six patients (12%) had recurrent disease in this series.
There were three local recurrences, one regional recur-
rence and two distant recurrences. Four histologic
subtypes were represented in this subgroup: sebaceous
adenocarcinoma (1 regional recurrence), eccrine adeno-
carcinoma (1 local recurrence), adenoid cystic carcin-
oma (1 local and 1 distant recurrence), and skin
appendage carcinoma (1 local and 1 distant recurrence).
Four of the patients with recurrent disease had their pri-
mary lesions located on the head and neck region while
the remaining two were located on the lower extrem-
ities. Recurrence-free survival analysis was done and
showed median RFS of 56 months. Five-year and
10-year RFS were 47.4% (95% CI 28.2–64.4) and 41.5%
(95% CI 22.21–59.8), respectively. Univariate analysis
showed age greater than 60 years, positive nodal status,
and advanced T stage as predictors of RFS, but only age
and positive nodal status persisted as independent pre-
dictors of RFS on multivariate analysis. Data on recur-
rence pattern is crucial to patient’s education about the
prognosis of these tumors. There is paucity of similar
data in the literature.
Conclusion
So far, there are few large population-based studies available
on malignant adnexal tumors of the skin (MATS). Most of
these were derived from the SEER database [1, 4, 5]. These
studies had the benefits of large study population and
broader representation of the population at large. They
were, however, not without their shortcomings which in-
cluded lack of uniform pathology reporting, absence of de-
tailed information about margin status, recurrences, and
selection criteria for nodal sampling, adjuvant chemother-
apy, and radiation treatment. We reviewed our 50-patient,
single-institution series and were able to address some of
these limitations, albeit with limited numbers.
This study shows that younger patients had better OS and
RFS. Absence of nodal metastasis was also noted to translate
to better RFS and DSS. Lymph node basin staging is worth
considering in the workup and treatment. More importantly,
strategies that promote early detection and prompt treat-
ment should be emphasized in addressing this disease.
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